The therapeutic index (TI) is a quantitative measure of the separation between the doses of a drug that produce a desired therapeutic effect and those that produce a specified toxic effect. In pharmacology, it is commonly expressed as the ratio of a median toxic dose to a median effective dose. A larger ratio generally indicates greater separation between these effects under the conditions studied, but it does not establish that a medicine is safe for every patient or every use.
Definition and calculation
A common definition is:
where:
- is the dose producing a specified toxic effect in 50% of the population studied.
- is the dose producing a specified therapeutic effect in 50% of that population.
In classical animal toxicology, the median lethal dose, , has also been used:
The lethal-dose formulation is primarily associated with preclinical research, not deliberate testing of lethal doses in humans. Clinical assessments instead use observed adverse effects, exposure–response relationships, and other evidence from clinical trials and clinical practice.
For illustration, if a defined therapeutic response occurs in half of a study population at 10 dose units and a defined toxic response occurs in half at 100 dose units, the therapeutic index is 10. The ratio is dimensionless when numerator and denominator use the same dose units. It does not mean that every individual can tolerate ten times an effective dose.
Both the therapeutic and toxic endpoints must be specified. A drug can have different therapeutic indices for different benefits, adverse effects, treatment durations, or routes of administration.
Dose–response interpretation
The therapeutic index is based on the dose–response relationship. For its conventional population-based calculation, the relevant responses are quantal: each individual either meets or does not meet a defined endpoint, such as achieving a specified treatment response or developing a particular toxic effect.
This use of differs from its use in some graded-response experiments, where it denotes the dose producing half the maximum response. The two meanings should not be treated as interchangeable without examining the experimental definition.
The ratio of two median doses does not describe the full shape of the response distributions. Two drugs can have the same therapeutic index but different degrees of overlap between effective and toxic doses. A sensitive subgroup may experience toxicity at doses below those required for benefit in another subgroup.
An alternative measure, sometimes called the certain safety factor, compares a low-percentile toxic dose with a high-percentile effective dose:
This emphasizes the separation between toxicity in susceptible individuals and effectiveness in most individuals. Such estimates require substantial data, and terminology for related safety measures varies.
Therapeutic index and therapeutic window
The therapeutic index is related to, but distinct from, the therapeutic window.
| Concept | Meaning |
|---|---|
| Therapeutic index | A ratio comparing doses associated with defined toxic and therapeutic responses |
| Therapeutic window | A range of doses or drug exposures associated with useful effects and acceptable toxicity |
| Therapeutic concentration range | A measured concentration interval associated with a specified balance of effectiveness and toxicity in a defined clinical setting |
A therapeutic window may be described in terms of blood concentration rather than administered dose. This distinction matters because pharmacokinetics determines how a dose translates into exposure, while pharmacodynamics describes how exposure relates to effects.
A concentration within a commonly used therapeutic range does not guarantee effectiveness or exclude toxicity. The relationship depends on the patient, indication, sampling time, and measurement method.
Narrow-therapeutic-index medicines
A narrow-therapeutic-index medicine has relatively little separation between exposures associated with benefit and those associated with serious toxicity or loss of effectiveness. Small changes in dose or exposure can therefore have important consequences.
Common examples include warfarin, lithium, digoxin, and certain calcineurin inhibitors, such as tacrolimus. These examples differ in how their effects are assessed. Warfarin’s anticoagulant effect is commonly evaluated using the international normalized ratio, whereas blood drug concentrations are used in monitoring several other narrow-therapeutic-index medicines.
There is no single numerical cutoff that defines all narrow-therapeutic-index medicines across regulatory systems. Classification can incorporate the steepness of exposure–response relationships, the severity of adverse outcomes, and the consequences of insufficient treatment.
Therapeutic drug monitoring measures drug concentrations to support interpretation of exposure. Its usefulness depends on an established concentration–response relationship and appropriate sampling. Not every medicine described as having a narrow therapeutic index is managed primarily through concentration measurement.
Factors affecting clinical interpretation
The practical separation between benefit and harm varies with several factors:
- Drug disposition: changes in absorption, distribution, metabolism, or elimination can alter exposure at an unchanged dose.
- Organ function: impaired kidney or liver function can reduce elimination of some drugs or their active metabolites.
- Interactions: drug interactions can change concentrations or intensify effects without changing concentrations.
- Biological variation: age, disease state, and genetic differences can affect drug handling or sensitivity. Some of these differences are studied in pharmacogenomics.
- Duration and schedule: repeated administration may cause accumulation, while some toxic effects depend on cumulative exposure.
- Treatment context: the acceptable balance of benefit and toxicity depends on the condition being treated and the available alternatives.
These factors explain why a therapeutic index obtained under one set of conditions is not a universal constant applicable to every clinical situation.
Applications and limitations
In drug development, therapeutic-index assessments help compare candidate compounds and characterize the separation between desired and harmful effects. Translation from animal experiments to humans remains limited by differences in metabolism, target biology, and susceptibility to toxicity.
The concept is particularly relevant to treatments such as chemotherapy, where effects on healthy tissues can occur near exposures required for antitumor activity. A limited therapeutic separation does not by itself establish whether a treatment has an acceptable benefit–risk balance.
The therapeutic index is not equivalent to potency, efficacy, or overall clinical value. A potent drug acts at a low dose but does not necessarily have a wide safety margin. The index also does not, by itself, describe rare immune-mediated reactions, delayed toxicity, reproductive effects, or the full range of possible adverse outcomes. Evidence from pharmacovigilance can identify harms that were not apparent in the studies used to characterize a drug’s initial safety profile.